Launch readiness

A launch isn't a moment. It's a window.

Launch readiness planning
24
18
12
6
0
+6
Strategic foundation
Brand plan & access
Commercial build-out
Readiness diagnostics  iterative
Day-one launch lock
Launch execution & monitoring
↑ Launch
Months to launch
Pharmamosaic

A launch is never one decision. It is hundreds of decisions compressed into an eighteen-to-twenty-four-month window, and the ones that shape whether the launch works are usually made a year before the approval letter arrives.

The work looks sequential when it's drawn on a slide. It isn't. Strategic foundation, brand plan, market access, commercial build-out — all run in parallel, with handoffs that only work if the teams were aligned from the start. Readiness is iterative, not a single pre-launch review.

We sit inside this window with commercial and launch leaders. Build the plan at T−24 or T−18, execute against it through the build phase, hold the discipline through day-one lock, and adjust through the first six months post-launch.

Typical engagements run six to sixteen weeks within this window, scoped to the decision at hand — a brand plan, a readiness diagnostic, a go-to-market architecture, or a commercial operating model. Led by senior people throughout.

Go-to-market structure

Build, buy, or hybrid. The choice that shapes the next five years.

A commercial structure decision is a tradeoff, not a template. Vertical integration retains strategic control and captures the upside, but ties up capital and takes years to stand up. Licensing accelerates access to revenue but surrenders control and long-term value. Hybrid structures capture much of both — but only when the seam is drawn at the right function.

The question is never really build-versus-buy. It is: which functions to own end-to-end, which to license or partner, where the seams sit, and how the structure will flex as the asset matures.

We help teams make the structural decision deliberately — with a clear view of where the partner dependencies will show up during launch, where the internal capability gaps will need to be closed in the first twelve months post-approval, and how much of the long-term NPV is left on the table under each path.

Tradeoffs across structures
Build
Buy
Hybrid
Strategic control
High
Low
Targeted
Upside potential
High
Low
Medium
Capital commitment
High
Low
Medium
Partner dependency
None
High
Targeted
Capability retention
Full
None
Partial
Indicative, asset-dependent
Pharmamosaic